CGON Stock Price | CG Oncology, Inc. Common stock P/E, Revenue, EPS, & Forecasts

CG Oncology, Inc. Common stock • CGON

CGON current price

$34.48-7.24%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-4.38%

-4.73%

-2.63%

-13.26%

-7.24%

MAX

-7.24%

About CG Oncology, Inc. Common stock

Ticker

CGON

Trading on

NASDAQ

ISIN

US1569441009

Industry

Biotechnology

Sector

Healthcare

CEO

Arthur Kuan

Headquarters

400 Spectrum Center Drive, Irvine, CA, United States, 92618

Employees

Website

https://cgoncology.com

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Metrics

BasicAdvanced

Market cap

$2.4B

P/E ratio

EPS

$0.00

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-68.2M

Ex dividend date

Price & volume

Market cap

$2.4B

Average daily volume

90-day return

-2.63%

30-day return

-4.73%

7-day return

-4.38%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

$0.00

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

4,450.92

Price to book

4.22

Earnings

EPS

$0.00

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-68.2M

Revenues (TTM)

$0.5M

Revenues per share (TTM)

$0.04

Technicals

Beta

52-week High

$50.23

52-week Low

$25.77

50-day moving average

$35.55

200-day moving average

$37.93

Short ratio

4.11

Short %

4.27%

Management effectiveness

ROE (TTM)

0.00%

ROA (TTM)

0.00%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

4,247.45%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

172.70%

Share stats

Outstanding Shares

$66.6M

Float

$43.7M

Insiders %

7.05%

Institutions %

72.12%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$68.20

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.33

-$0.67

50.61%

Q4 • 23Beat

-$0.36

-$0.29

24.14%

Q1 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.5M

$-16.9M

3,200.76%

Q1 • 24

$0.1M

$-18.9M

17,028.83%

Q2 • 24

79.02%

11.63%

432.03%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$579M

$10.2M

1.76%

Q1 • 24

$564M

$12M

2.12%

Q2 • 24

2.55%

17.73%

20.82%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-26M

$-307M

$403M

$-26M

Q1 • 24

$-16.1M

$-36.2M

$0M

$-16.1M

Q2 • 24

38.03%

88.22%

99.99%

38.00%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a CG Oncology, Inc. Common stock share?

CG Oncology, Inc. Common stock shares are currently traded for $34.48 per share.

How many shares does CG Oncology, Inc. Common stock have?

CG Oncology, Inc. Common stock currently has $66.6M shares.

Does CG Oncology, Inc. Common stock pay dividends?

No, CG Oncology, Inc. Common stock doesn't pay dividends.

What is CG Oncology, Inc. Common stock 52 week high?

CG Oncology, Inc. Common stock 52 week high is $50.23.

What is CG Oncology, Inc. Common stock 52 week low?

CG Oncology, Inc. Common stock 52 week low is $25.77.

What is the 200-day moving average of CG Oncology, Inc. Common stock?

CG Oncology, Inc. Common stock 200-day moving average is $37.93.

Who is CG Oncology, Inc. Common stock CEO?

The CEO of CG Oncology, Inc. Common stock is Arthur Kuan.

How many employees CG Oncology, Inc. Common stock has?

CG Oncology, Inc. Common stock has 61 employees.

What is the market cap of CG Oncology, Inc. Common stock?

The market cap of CG Oncology, Inc. Common stock is $2.4B.

What is the P/E of CG Oncology, Inc. Common stock?

The current P/E of CG Oncology, Inc. Common stock is null.

What is the EPS of CG Oncology, Inc. Common stock?

The EPS of CG Oncology, Inc. Common stock is $0.00.

What is the PEG Ratio of CG Oncology, Inc. Common stock?

The PEG Ration of CG Oncology, Inc. Common stock is null.

What do analysts say about CG Oncology, Inc. Common stock?

According to the analysts CG Oncology, Inc. Common stock is considered a buy.

CG Oncology, Inc. Common stock news

thumbs_up_down

•Neutral

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.

GlobeNewsWire•30 Aug 2024, 12:00

thumb_up_alt

•Positive

CG Oncology: Promising Data, But Looks Expensive

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by selectively replicating in cancer cells and encoding GM-CSF to activate the immune system. The market potential for cretostimogene is significant, targeting BCG-unresponsive NMIBC patients with a multi-billion dollar opportunity.

Seeking Alpha•26 Aug 2024, 14:34

thumbs_up_down

•Neutral

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing – IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.

GlobeNewsWire•08 Aug 2024, 12:23

Invest your money to its potential

When you invest your capital is at risk.